• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AIZU OLYMPUS CO., LTD. EVIS LUCERA GASTROINTESTINAL VIDEOSCOPE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AIZU OLYMPUS CO., LTD. EVIS LUCERA GASTROINTESTINAL VIDEOSCOPE Back to Search Results
Model Number GIF-Q260J
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Internal Organ Perforation (1987)
Event Date 01/27/2024
Event Type  Injury  
Manufacturer Narrative
This report is related to the following linked patient identifiers: (b)(6).The author was not reachable to obtain any further information.The investigation is ongoing, and this report will be supplemented when new and relevant information becomes available later.
 
Event Description
Olympus medical systems corp.(omsc) received a literature titled "a study of ingenuity of esd for early gastric cancer in s-8 aosagisatsu region".Background and objectives: the u region is considered a difficult site for esd in early-stage gastric cancer.The difficulty of esd is particularly high in the nodal region.The reasons for this include easy submersion, thin gastric wall, difficulty in proximity, and lesions facing each other.On the other hand, esd has become possible even in the mandibular region with the use of traction devices and a wide variety of knives and scopes in recent years.We will review the results of esd in our clinic and explore effective esd techniques.Methods: we retrospectively reviewed the results of esd and details of the technique in 24 cases of early gastric cancer located in the nuchal region out of 1818 cases and 2281 lesions of early gastric cancer esd performed at our hospital from february 2004 to september 2023.The gif-q260j and gif-h290t scopes were defined as standard scopes, and the other scopes were defined as special scopes.Results: results: median age 66 years, gender (male/female) 16/8, gross type: 0-ila 8 cases, 0-ilb 8 cases, 0-ilc 8 cases, h.Pylori: negative 15 cases, positive 9 cases, site: anterior wall 1 case, posterior wall 5 cases, large crossbow 10 cases, apical 8 cases, postoperative reconstructed stomach 2 cases.Median resection lesion diameter was 14 mm, median resection specimen diameter was 36 mm, depth (m/sm1/sm2) was 14/5/5, ul was 1 case, and positive vascular invasion was 1 case.The median treatment time was 141 minutes, and all patients underwent complete en bloc resection.No posterior hemorrhage or delayed perforation was observed.Intraoperative perforation was observed in 4 patients (17%), but it could be treated conservatively.Details of the procedure: all patients received co2 insufflation, 3 high-frequency knives (flash knife bt 1.5mm or 2.Omm, it knife 2, and clutch cutter), traction method in 6 cases without and 18 cases with, special scope in 7 cases pcf260ji and qt2604.In the perforation cases, none of the 4 cases used the special scope, and 3 cases were located at the apex, and the technique was performed in the field of view with the knife facing the muscle layer.Perforation in cases using the special scope was 0%, whereas perforation with the normal scope was 31% (p=o.098).The use of the special scope was considered to be a factor in avoiding perforation because it provided a field of view parallel to the muscle layer.Conclusion: although the rate of esd perforation in the nodal region is as high as 17% and the choice of treatment method requires more careful consideration, the use of a special scope may reduce the risk of esd perforation.Type of adverse events/number of patients.Intraoperative perforation (n=4).
 
Manufacturer Narrative
This report is being supplemented to provide additional information based on the legal manufacturer's final investigation.The device history record was unable to be reviewed for this device since the serial and/or lot number was not provided.However, olympus only releases products to market that meet all manufacturing specifications and final product release criteria.Based on the results of the investigation, a relationship between the device and the adverse event cannot be confirmed.There was no complaint reported on the subject device.There is no evidence of an olympus device malfunction.Therefore, the root cause cannot be determined.Olympus will continue to monitor field performance for this device.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EVIS LUCERA GASTROINTESTINAL VIDEOSCOPE
Type of Device
GASTROINTESTINAL VIDEOSCOPE
Manufacturer (Section D)
AIZU OLYMPUS CO., LTD.
3-1-1 niiderakita
aizuwakamatsu-shi, fukushima 965-8 520
JA  965-8520
Manufacturer (Section G)
AIZU OLYMPUS CO., LTD.
3-1-1 niiderakita
aizuwakamatsu-shi, fukushima
Manufacturer Contact
todd brill
800 west park drive
westborough, MA 01581
5082077661
MDR Report Key18884892
MDR Text Key337417372
Report Number9610595-2024-05219
Device Sequence Number1
Product Code FDS
Combination Product (y/n)N
Reporter Country CodeJA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Study,Literature,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial,Followup
Report Date 03/21/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/12/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberGIF-Q260J
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received03/21/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Reuse
Patient Sequence Number1
Treatment
GIF-H290T; KD-611L
Patient Outcome(s) Other;
-
-